Madrigal Pharmaceuticals Statistics
Share Statistics
Madrigal Pharmaceuticals has 21.81M shares outstanding. The number of shares has increased by 9.98% in one year.
| Shares Outstanding | 21.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.88% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 18.39M |
| Failed to Deliver (FTD) Shares | 50 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.53M, so 20.78% of the outstanding shares have been sold short.
| Short Interest | 4.53M |
| Short % of Shares Out | 20.78% |
| Short % of Float | 24.65% |
| Short Ratio (days to cover) | 13.46 |
Valuation Ratios
The PE ratio is -11.57 and the forward PE ratio is -24.29.
| PE Ratio | -11.57 |
| Forward PE | -24.29 |
| PS Ratio | 0 |
| Forward PS | 13.9 |
| PB Ratio | 10.67 |
| P/FCF Ratio | -13.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Madrigal Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.38, with a Debt / Equity ratio of 0.29.
| Current Ratio | 5.38 |
| Quick Ratio | 5.38 |
| Debt / Equity | 0.29 |
| Total Debt / Capitalization | 22.25 |
| Cash Flow / Debt | -2.79 |
| Interest Coverage | -29.93 |
Financial Efficiency
Return on equity (ROE) is -0.92% and return on capital (ROIC) is -72.82%.
| Return on Equity (ROE) | -0.92% |
| Return on Assets (ROA) | -0.58% |
| Return on Capital (ROIC) | -72.82% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -993.70K |
| Employee Count | 376 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 27.55% in the last 52 weeks. The beta is -0.47, so Madrigal Pharmaceuticals 's price volatility has been lower than the market average.
| Beta | -0.47 |
| 52-Week Price Change | 27.55% |
| 50-Day Moving Average | 277.92 |
| 200-Day Moving Average | 255.37 |
| Relative Strength Index (RSI) | 46.81 |
| Average Volume (20 Days) | 412.40K |
Income Statement
In the last 12 months, Madrigal Pharmaceuticals had revenue of $0 and earned -$373.63M in profits. Earnings per share was $-19.99.
| Revenue | 0 |
| Gross Profit | -527.00K |
| Operating Income | -380.50M |
| Net Income | -373.63M |
| EBITDA | -379.97M |
| EBIT | - |
| Earnings Per Share (EPS) | -19.99 |
Balance Sheet
The company has $99.92M in cash and $117.19M in debt, giving a net cash position of -$17.28M.
| Cash & Cash Equivalents | 99.92M |
| Total Debt | 117.19M |
| Net Cash | -17.28M |
| Retained Earnings | -1.34B |
| Total Assets | 1.07B |
| Working Capital | 885.82M |
Cash Flow
In the last 12 months, operating cash flow was -$324.23M and capital expenditures -$1.48M, giving a free cash flow of -$325.71M.
| Operating Cash Flow | -324.23M |
| Capital Expenditures | -1.48M |
| Free Cash Flow | -325.71M |
| FCF Per Share | -17.43 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
MDGL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.61% |
| FCF Yield | -4.94% |
Analyst Forecast
The average price target for MDGL is $377, which is 24.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $377 |
| Price Target Difference | 24.6% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Stock Splits
The last stock split was on Jul 25, 2016. It was a backward split with a ratio of 1:35.
| Last Split Date | Jul 25, 2016 |
| Split Type | backward |
| Split Ratio | 1:35 |
Scores
| Altman Z-Score | 10.61 |
| Piotroski F-Score | 4 |